Curium Completes Patient Enrollment of Phase 3 ECLIPSE Trial Ahead of Schedule
ST. LOUIS, Nov. 23, 2023 (GLOBE NEWSWIRE) -- Curium, a global leader in nuclear medicine, announced today the successful completion of patient enrollment in the pivotal Phase 3 ECLIPSE trial. ECLIPSE is a Phase 3, multi-center, open-label, randomized …